CR9632A - Tableta que contiene un ingrediente dificilmente soluble - Google Patents

Tableta que contiene un ingrediente dificilmente soluble

Info

Publication number
CR9632A
CR9632A CR9632A CR9632A CR9632A CR 9632 A CR9632 A CR 9632A CR 9632 A CR9632 A CR 9632A CR 9632 A CR9632 A CR 9632A CR 9632 A CR9632 A CR 9632A
Authority
CR
Costa Rica
Prior art keywords
tablet containing
soluble ingredient
difficultly soluble
batch
tablet
Prior art date
Application number
CR9632A
Other languages
English (en)
Inventor
Marunaka Shigeyuki
Fukuta Makoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9632(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR9632A publication Critical patent/CR9632A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una tableta que muestra una variacion regulada en la elusion de lote a lote que contiene de aproximadamente 3 a aproximadamente 50% en peso (p/p), con base en la tableta completa de (S)-N-[2-(1,6,7,8-tetrahidro-2H-indeno[5,4-b]furan-8-il)etil]propionamida, estearato de magnesio e hidroxipropilcelulosa que tiene una viscosidad de aproximadamente 1 a aproximadamente 4 mPa.s.
CR9632A 2005-06-22 2007-12-21 Tableta que contiene un ingrediente dificilmente soluble CR9632A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005182415 2005-06-22
PCT/JP2006/312419 WO2006137443A1 (ja) 2005-06-22 2006-06-21 難溶性の有効成分を含有する錠剤

Publications (1)

Publication Number Publication Date
CR9632A true CR9632A (es) 2008-02-04

Family

ID=37570471

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9632A CR9632A (es) 2005-06-22 2007-12-21 Tableta que contiene un ingrediente dificilmente soluble

Country Status (17)

Country Link
US (1) US8821926B2 (es)
EP (1) EP1900368B1 (es)
JP (1) JP5220408B2 (es)
KR (1) KR20080027783A (es)
CN (1) CN101247805B (es)
AU (1) AU2006260201B2 (es)
BR (1) BRPI0611618A2 (es)
CA (1) CA2612090C (es)
CR (1) CR9632A (es)
ES (1) ES2366381T3 (es)
IL (1) IL187916A (es)
MX (1) MX2007015783A (es)
NO (1) NO20080248L (es)
NZ (1) NZ564407A (es)
RU (1) RU2420278C2 (es)
WO (2) WO2007004425A1 (es)
ZA (1) ZA200711048B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102813635A (zh) * 2006-08-10 2012-12-12 武田药品工业株式会社 药物组合物
WO2009084023A2 (en) * 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
PL2389164T3 (pl) * 2009-01-21 2015-01-30 Hoffmann La Roche Kompozycje farmaceutyczne zawierające prolek inhibitora polimerazy HCV
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
CN103989643B (zh) * 2013-07-26 2018-10-30 武汉先路医药科技有限公司 含有雷美替胺和共聚维酮的片剂
CN104546746A (zh) * 2013-10-28 2015-04-29 南京长澳医药科技有限公司 一种雷美替胺片剂及其制备工艺
JP7576905B2 (ja) 2016-05-06 2024-11-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー バレリアン組成物及び関連方法
JP7407364B2 (ja) * 2019-02-12 2024-01-04 日本ジェネリック株式会社 ラメルテオン含有固形製剤
US20250381143A1 (en) * 2021-12-30 2025-12-18 Adlai Nortye Biopharma Co., Ltd. A solid pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1997032871A1 (en) * 1996-03-08 1997-09-12 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JPH11322584A (ja) * 1998-05-07 1999-11-24 Sawai Pharmaceutical Co Ltd ベザフィブラート徐放性製剤
US6348485B1 (en) * 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
AU6589200A (en) * 1999-09-10 2001-04-17 Ranbaxy Laboratories Limited Extended release formulation of etodolac
AU2002214305A1 (en) * 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Pharmaceutical preparation containing copolyvidone
JP4848558B2 (ja) * 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
JP4754211B2 (ja) 2004-12-28 2011-08-24 ライオン株式会社 粒状医薬組成物及びその製造方法

Also Published As

Publication number Publication date
KR20080027783A (ko) 2008-03-28
JPWO2006137443A1 (ja) 2009-01-22
ZA200711048B (en) 2009-05-27
AU2006260201B2 (en) 2011-10-20
AU2006260201A1 (en) 2006-12-28
WO2007004425A1 (ja) 2007-01-11
US20090036522A1 (en) 2009-02-05
US8821926B2 (en) 2014-09-02
CN101247805B (zh) 2012-10-10
CN101247805A (zh) 2008-08-20
IL187916A0 (en) 2008-03-20
MX2007015783A (es) 2008-02-21
ES2366381T3 (es) 2011-10-19
RU2008102238A (ru) 2009-07-27
NZ564407A (en) 2011-03-31
NO20080248L (no) 2008-01-14
BRPI0611618A2 (pt) 2011-05-31
RU2420278C2 (ru) 2011-06-10
EP1900368A1 (en) 2008-03-19
CA2612090C (en) 2014-06-10
WO2006137443A1 (ja) 2006-12-28
EP1900368B1 (en) 2011-05-11
CA2612090A1 (en) 2006-12-28
IL187916A (en) 2013-11-28
EP1900368A4 (en) 2009-08-12
JP5220408B2 (ja) 2013-06-26
HK1115315A1 (en) 2008-11-28

Similar Documents

Publication Publication Date Title
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
HUS1600032I1 (hu) Triterpéntartalmú oleogélképzõ, triterpéntartalmú oleogél és eljárás triterpéntartalmú oleogél elõállítására
CO6400186A2 (es) Tabletas de acetato de ulipristal
CY1115838T1 (el) Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους
CY1107451T1 (el) Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
NO20080248L (no) Tablett inneholdende lite opploselig, aktiv bestanddel
SG170081A1 (en) Method of patterning and product(s) obtained therefrom
BR112014014127A2 (pt) composições de higiene bucal
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
CR9211A (es) Composiciones que comprenden una epotilona y metodos de produccion
BRPI0516464A (pt) formulação farmacêutica, método para a preparação de um produto farmacêutico, e, uso de uma formulação farmacêutica
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
DK1503803T3 (da) Injicerbar farmaceutisk sammensætning indeholdende ethanol til at behandle diskusprolaps
AR062375A1 (es) Cristal de epotilona b y composiciones farmaceuticas
DK1626726T3 (da) Anvendelse af lornoxicam eller lornoxicam-analoger
EA200500613A1 (ru) Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция